Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.15
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.15
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.25
Previous CloseN/A
Volume145.39K
Average Volume (3M)112.21K
Market Cap
C$7.25M
Enterprise ValueC$13.07T
Total Cash (Recent Filing)C$434.80K
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding63,028,290
10 Day Avg. Volume135,978
30 Day Avg. Volume112,209
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Net LossThe reduced annual loss indicates some progress in controlling expenses or limiting deterioration. However, the improvement is not yet sufficient to establish a sustainable earnings profile because the company still has no revenue and remains loss-making.
Lower Cash BurnA lower cash burn rate can extend the company’s operating runway and reduce near-term financing pressure. The benefit is durable only if management can continue improving cash efficiency while advancing the business toward commercial revenue.
Debt ReductionDebt reduction modestly improves the capital structure and may reduce future interest or repayment pressure. This provides some financial benefit, although the company’s small asset base and negative equity still leave limited flexibility.
Bears Say
No Revenue BaseThe absence of revenue is a fundamental commercialization risk for a biotechnology company. Without an established revenue stream, operating costs cannot be self-funded, making long-term sustainability dependent on successful development, partnerships, or external capital.
Negative Shareholders’ EquityNegative equity signals accumulated losses and a very thin capital cushion. It limits financial resilience, can make future financing more difficult or dilutive, and increases the risk that additional capital will be needed before the business reaches commercial scale.
Persistent Negative Free Cash FlowPersistent negative free cash flow shows that operations are consuming rather than generating capital. Even with some improvement in the burn rate, continued reliance on financing creates dilution and liquidity risk unless revenue generation or operating economics improve materially.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.10 and its highest was C$0.25 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$7.25M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Nov 26, 2026 which is in 46 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Jun 18, 2026. The company reported C$0.007 earnings per share for the quarter.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of C$0.007 in its last earnings report. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.